G. Zaman

发表

G. Zaman, 2004, Combinatorial chemistry & high throughput screening.

Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors

M. Sawa, G. Zaman, J. de Man, 2016, Molecular Cancer Therapeutics.

Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity.

G. Zaman, J. de Man, R. Buijsman, 2017, Journal of molecular biology.

MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance

A. Ferrando, R. Pieters, J. Meijerink, 2021, Leukemia.

Enzyme fragment complementation binding assay for p38alpha mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors.

G. Zaman, M. V. D. van der Lee, E. Loomans, 2006, Assay and drug development technologies.

β‐Galactosidase enzyme fragment complementation for the measurement of Wnt/β‐catenin signaling

W. Blankesteijn, J. Smits, G. Zaman, 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

A model for signaling specificity of Wnt/Frizzled combinations through co‐receptor recruitment

G. Zaman, F. Verkaar, 2010, FEBS letters.

Quantitative proteomic and phosphoproteomic comparison of human colon cancer DLD-1 cells differing in ploidy and chromosome stability

L. Bubendorf, Z. Storchová, A. Schmidt, 2018, Molecular biology of the cell.

High-Throughput Fluorescence-Based Activity Assay for Arginase-1

G. Zaman, J. de Man, R. Buijsman, 2020, SLAS discovery : advancing life sciences R & D.

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017

M. Sawa, G. Zaman, J. de Man, 2018, Molecular Cancer Therapeutics.

IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study

Andrew P. Stubbs, R. Pieters, W. Dinjens, 2016, PLoS medicine.

Discovery of Novel Small Molecule Activators of β-Catenin Signaling

M. van der Stelt, W. Blankesteijn, G. Zaman, 2011, PloS one.

High-throughput screening using beta-lactamase reporter-gene technology for identification of low-molecular-weight antagonists of the human gonadotropin releasing hormone receptor.

G. Zaman, M. Blomenröhr, J. Oosterom, 2005, Assay and drug development technologies.

Chemokine Cooperativity Is Caused by Competitive Glycosaminoglycan Binding

T. Handel, B. Volkman, H. Vischer, 2014, The Journal of Immunology.

Nonpeptidergic Allosteric Antagonists Differentially Bind to the CXCR2 Chemokine Receptor

R. Leurs, D. Auld, M. Ohlmeyer, 2009, Journal of Pharmacology and Experimental Therapeutics.

CXCR2 antagonists block the N-Ac-PGP-induced neutrophil influx in the airways of mice, but not the production of the chemokine CXCL1.

A. Kraneveld, J. Garssen, G. Folkerts, 2011, European journal of pharmacology.

Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158

G. Zaman, J. de Man, R. Buijsman, 2019, Journal of structural biology: X.

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

Joost C. M. Uitdehaag, G. Zaman, Y. Narumi, 2022, Frontiers in Oncology.

Non-peptidergic allosteric antagonists differentially bind to the CXCR 2 chemokine receptor

R. Leurs, D. Auld, M. Ohlmeyer, 2009 .

Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.

J. Mestres, R. Morphy, G. Zaman, 2011, Bioorganic & medicinal chemistry letters.

The collagen-breakdown product N-acetyl-Proline-Glycine-Proline (N-alpha-PGP) does not interact directly with human CXCR1 and CXCR2.

R. Leurs, A. Kraneveld, M. Smit, 2010, European journal of pharmacology.

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors

J. Crown, G. Zaman, D. Collins, 2021, British Journal of Cancer.

Cryopreserved cells facilitate cell-based drug discovery.

G. Zaman, M. Blomenröhr, J. D. de Roos, 2007, Drug discovery today.

β-Arrestin Recruitment and G Protein Signaling by the Atypical Human Chemokine Decoy Receptor CCX-CKR*

R. Leurs, H. Vischer, M. Smit, 2013, The Journal of Biological Chemistry.

Noncompetitive Antagonism and Inverse Agonism as Mechanism of Action of Nonpeptidergic Antagonists at Primate and Rodent CXCR3 Chemokine Receptors

I. D. de Esch, R. Leurs, M. Smit, 2008, Journal of Pharmacology and Experimental Therapeutics.

High-Throughput Fluorescence-Based Screening Assays for Tryptophan-Catabolizing Enzymes

G. Zaman, J. de Man, R. Buijsman, 2014, Journal of biomolecular screening.

A signaling-selective, nanomolar potent allosteric low molecular weight agonist for the human luteinizing hormone receptor

Jan Kelder, Guido J. R. Zaman, M. Smit, 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

Targeting RNA: new opportunities to address drugless targets.

P. Michiels, G. Zaman, C. V. van Boeckel, 2003, Drug discovery today.

Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies

A. Ferrando, J. Meijerink, S. Piersma, 2022, Nature communications.

Amino Acid-Metabolizing Enzymes in Advanced High-Grade Serous Ovarian Cancer Patients: Value of Ascites as Biomarker Source and Role for IL4I1 and IDO1

A. Kraneveld, A. V. van Altena, G. Zaman, 2023, Cancers.

Chromosomal instability, tolerance of mitotic errors and multidrug resistance are promoted by tetraploidization in human cells

W. Kloosterman, S. Müller, Z. Storchová, 2015, Cell cycle.

TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers

G. Zaman, J. de Man, R. Buijsman, 2017, Molecular Cancer Therapeutics.

Inhibition of Wnt/β-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Iδ/ɛ.

W. Blankesteijn, J. Smits, G. Zaman, 2011, Chemistry & biology.

Characterization and optimization of a red-shifted fluorescence polarization ADP detection assay.

J. Hornberg, T. Klink, G. Zaman, 2009, Assay and drug development technologies.

High-throughput screening with immobilized metal ion affinity-based fluorescence polarization detection, a homogeneous assay for protein kinases.

G. Zaman, A. V. van Doornmalen, E. Loomans, 2003, Assay and drug development technologies.

New avenues to target Wnt/β-catenin signaling.

G. Zaman, F. Verkaar, 2011, Drug discovery today.

Molecular Mechanisms of Wnt Pathway Specificity

G. Zaman, F. Verkaar, A. Schambony, 2014 .

Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use

K. Yoshino, G. Zaman, J. de Man, 2014, PloS one.

Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites

A. V. van Altena, G. Zaman, R. Buijsman, 2020, Oncotarget.

MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia

J. Meijerink, R. Pieters, Joost C. M. Uitdehaag, 2016, Leukemia.

Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies

A. Ferrando, J. Meijerink, S. Piersma, 2022, Nature Communications.

Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines

B. Tops, R. Medema, Z. Storchová, 2017, Oncotarget.

Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0

L. Massuger, A. V. van Altena, G. Zaman, 2021, Frontiers in Immunology.

Correction: Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs

G. Zaman, J. de Man, R. Buijsman, 2015, PloS one.

Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine.

S. Laufer, G. Zaman, D. Rauh, 2017, Journal of medicinal chemistry.

β-Arrestin Recruitment Assay for the Identification of Agonists of the Sphingosine 1-Phosphate Receptor EDG1

G. Zaman, M. V. D. van der Lee, C. V. van Koppen, 2008, Journal of biomolecular screening.

Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.

R. Medema, Joost C. M. Uitdehaag, J. Jonkers, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

β-Arrestin-biased signaling of PTH analogs of the type 1 parathyroid hormone receptor.

G. Zaman, M. V. D. van der Lee, F. Verkaar, 2013, Cellular signalling.

Ligand-induced folding of the guanine-sensing riboswitch is controlled by a combined predetermined induced fit mechanism.

S. Wijmenga, H. Heus, S. Rampersad, 2007, RNA.

Pharmacological Characterization of Receptor Redistribution and β-Arrestin Recruitment Assays for the Cannabinoid Receptor 1

G. Zaman, M. Blomenröhr, M. V. D. van der Lee, 2009, Journal of biomolecular screening.

G protein-independent cell-based assays for drug discovery on seven-transmembrane receptors.

W. Blankesteijn, J. Smits, G. Zaman, 2008, Biotechnology annual review.

Pharmacological validation of TDO as a target for Parkinson’s disease

A. Kraneveld, R. Pasterkamp, G. Zaman, 2021, The FEBS journal.

Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance.

M. Sawa, G. Zaman, J. de Man, 2017, Journal of molecular biology.

Optimierte Bindungsdauer am Zielenzym: Typ-I1/2 -Inhibitoren der p38α-MAP-Kinase mit verbesserter Bindungskinetik durch direkte Interaktion mit der R-Spine

L. Zender, S. Laufer, G. Zaman, 2017 .

Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine.

Stefan Laufer, Daniel Rauh, Daniel Dauch, 2017, Angewandte Chemie.

A theoretical entropy score as a single value to express inhibitor selectivity

Joost C. M. Uitdehaag, Guido J. R. Zaman, G. Zaman, 2011, BMC Bioinformatics.

Identification of a Novel Allosteric Binding Site in the CXCR2 Chemokine Receptor

R. Leurs, D. Auld, C. de Graaf, 2011, Molecular Pharmacology.

Microsoft Word-38368250-file00.docx

R. Leurs, D. Auld, M. Smit, 2011 .

Compound selectivity and target residence time of kinase inhibitors studied with surface plasmon resonance

M. Sawa, G. Zaman, R. Buijsman, 2016 .

A prospective cross-screening study on G-protein-coupled receptors: lessons learned in virtual compound library design.

Andreas Bender, Stefan Verhoeven, Ross McGuire, 2012, Journal of medicinal chemistry.

High-Throughput Screening Using β-Lactamase Reporter-Gene Technology for Identification of Low-Molecular-Weight Antagonists of the Human Gonadotropin Releasing Hormone Receptor

G. Zaman, J. Oosterom, S. Lobregt, 2005 .

N-acetylated Proline-Glycine-Proline induced G-protein dependent chemotaxis of neutrophils is independent of CXCL8 release.

A. Kraneveld, J. Garssen, M. Smit, 2011, European journal of pharmacology.

Controversies in ASSAY and drug development technologies: a focus on assessing irreproducibility.

A. Simeonov, A. Napper, T. Lundbäck, 2014, Assay and drug development technologies.

Recent developments in the supply of cells for screening and new assay technologies are changing the view that working with living cells is labour intensive and ‘ a little bit tricky ’ . Cryopreserved cells facilitate cell-based drug discovery

G. Zaman, J. Oosterom, C. Koppen, 2007 .

C5a-Stimulated Recruitment of β-Arrestin2 to the Nonsignaling 7-Transmembrane Decoy Receptor C5L2

G. Zaman, A. van Elsas, Guido J R Zaman, 2009, Journal of biomolecular screening.

Fluorescence assays for high-throughput screening of protein kinases.

T. de Boer, G. Zaman, C. V. van Boeckel, 2003, Combinatorial chemistry & high throughput screening.

Abstract 3502: Selective targeting of CTNBB1-, KRAS- or MYC-driven cell growth by combinations of existing drugs

G. Zaman, R. Buijsman, J. Uitdehaag, 2015 .

Screening for Modulators of G Protein-Coupled Receptors.

G. Zaman, 2005, Combinatorial chemistry & high throughput screening.

T-Cell Acute Lymphoblastic Leukemia Patients with Mutations in IL7Ra or Downstream RAS-MEK or PI3K-AKT Can be Collectively Targeted By Combination of RAS and AKT Inhibitors

R. Pieters, J. Meijerink, G. Zaman, 2015 .

Stably overexpressed human Frizzled-2 signals through the beta-catenin pathway and does not activate Ca2+-mobilization in Human Embryonic Kidney 293 cells.

W. Blankesteijn, J. Smits, G. Zaman, 2009, Cellular signalling.

Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor

G. Zaman, J. Kooijman, J. V. Van Tornout, 2023, Cancer Chemotherapy and Pharmacology.

Abstract 2849: Analysis of the cancer gene targeting of clinical kinase inhibitor drugs by combining cellular and biochemical profiling

K. Yoshino, G. Zaman, R. Buijsman, 2014 .

Nonpeptidergic Allosteric Antagonists Differentially Bind to the CXCR2 Chemokine Receptor

R. Leurs, D. Auld, M. Ohlmeyer, 2009, Journal of Pharmacology and Experimental Therapeutics.

Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination

Adrian Brüngger, L. Kellenberger, F. Bachmann, 2024, Frontiers in oncology.